nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—PTGS2—head and neck cancer	0.576	1	CbGaD
Naproxen—ALB—Fluorouracil—head and neck cancer	0.049	0.344	CbGbCtD
Naproxen—CYP2C8—Fluorouracil—head and neck cancer	0.0378	0.266	CbGbCtD
Naproxen—CYP1A2—Fluorouracil—head and neck cancer	0.0293	0.206	CbGbCtD
Naproxen—CYP2C9—Fluorouracil—head and neck cancer	0.0264	0.185	CbGbCtD
Naproxen—AKR1C3—Vincristine—Vinblastine—head and neck cancer	0.00564	1	CbGdCrCtD
Naproxen—Ibuprofen—BCL2—head and neck cancer	0.00169	0.225	CrCbGaD
Naproxen—Nabumetone—PTGS2—head and neck cancer	0.00134	0.178	CrCbGaD
Naproxen—Carprofen—PTGS2—head and neck cancer	0.00127	0.17	CrCbGaD
Naproxen—Suprofen—PTGS2—head and neck cancer	0.000788	0.105	CrCbGaD
Naproxen—Haemorrhage—Vinblastine—head and neck cancer	0.000705	0.00369	CcSEcCtD
Naproxen—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000702	0.00367	CcSEcCtD
Naproxen—Dermatitis bullous—Fluorouracil—head and neck cancer	0.000699	0.00366	CcSEcCtD
Naproxen—Pharyngitis—Vinblastine—head and neck cancer	0.000699	0.00366	CcSEcCtD
Naproxen—Hearing impaired—Docetaxel—head and neck cancer	0.000698	0.00365	CcSEcCtD
Naproxen—Stomatitis—Hydroxyurea—head and neck cancer	0.000698	0.00365	CcSEcCtD
Naproxen—Bone pain—Docetaxel—head and neck cancer	0.000694	0.00363	CcSEcCtD
Naproxen—Inflammation—Docetaxel—head and neck cancer	0.000685	0.00359	CcSEcCtD
Naproxen—Cardiac failure—Fluorouracil—head and neck cancer	0.000685	0.00358	CcSEcCtD
Naproxen—Fenoprofen—PTGS2—head and neck cancer	0.000679	0.0905	CrCbGaD
Naproxen—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000677	0.00354	CcSEcCtD
Naproxen—Osteoarthritis—Fluorouracil—head and neck cancer	0.000668	0.0035	CcSEcCtD
Naproxen—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000668	0.0035	CcSEcCtD
Naproxen—Haemoglobin—Hydroxyurea—head and neck cancer	0.000646	0.00338	CcSEcCtD
Naproxen—Influenza like illness—Docetaxel—head and neck cancer	0.000646	0.00338	CcSEcCtD
Naproxen—Haemorrhage—Hydroxyurea—head and neck cancer	0.000642	0.00336	CcSEcCtD
Naproxen—Hallucination—Hydroxyurea—head and neck cancer	0.000639	0.00334	CcSEcCtD
Naproxen—Colitis—Docetaxel—head and neck cancer	0.000638	0.00334	CcSEcCtD
Naproxen—Skin exfoliation—Docetaxel—head and neck cancer	0.000635	0.00332	CcSEcCtD
Naproxen—Alopecia—Vinblastine—head and neck cancer	0.000623	0.00326	CcSEcCtD
Naproxen—Dry skin—Fluorouracil—head and neck cancer	0.000613	0.00321	CcSEcCtD
Naproxen—Oesophagitis—Docetaxel—head and neck cancer	0.000607	0.00318	CcSEcCtD
Naproxen—Lightheadedness—Docetaxel—head and neck cancer	0.000595	0.00311	CcSEcCtD
Naproxen—Pulmonary oedema—Docetaxel—head and neck cancer	0.000592	0.0031	CcSEcCtD
Naproxen—Muscular weakness—Fluorouracil—head and neck cancer	0.00059	0.00308	CcSEcCtD
Naproxen—Angiopathy—Hydroxyurea—head and neck cancer	0.000583	0.00305	CcSEcCtD
Naproxen—Dysphagia—Fluorouracil—head and neck cancer	0.000578	0.00302	CcSEcCtD
Naproxen—Sepsis—Docetaxel—head and neck cancer	0.000577	0.00302	CcSEcCtD
Naproxen—Chills—Hydroxyurea—head and neck cancer	0.000576	0.00302	CcSEcCtD
Naproxen—Eosinophilia—Fluorouracil—head and neck cancer	0.000572	0.00299	CcSEcCtD
Naproxen—Ill-defined disorder—Vinblastine—head and neck cancer	0.000569	0.00298	CcSEcCtD
Naproxen—Alopecia—Hydroxyurea—head and neck cancer	0.000568	0.00297	CcSEcCtD
Naproxen—Anaemia—Vinblastine—head and neck cancer	0.000567	0.00297	CcSEcCtD
Naproxen—Angina pectoris—Fluorouracil—head and neck cancer	0.000563	0.00294	CcSEcCtD
Naproxen—Erythema—Hydroxyurea—head and neck cancer	0.000559	0.00293	CcSEcCtD
Naproxen—Thrombophlebitis—Docetaxel—head and neck cancer	0.000557	0.00292	CcSEcCtD
Naproxen—Malaise—Vinblastine—head and neck cancer	0.000553	0.00289	CcSEcCtD
Naproxen—Vertigo—Vinblastine—head and neck cancer	0.000551	0.00288	CcSEcCtD
Naproxen—Leukopenia—Vinblastine—head and neck cancer	0.000549	0.00287	CcSEcCtD
Naproxen—Pancytopenia—Fluorouracil—head and neck cancer	0.000549	0.00287	CcSEcCtD
Naproxen—Swelling—Docetaxel—head and neck cancer	0.000547	0.00286	CcSEcCtD
Naproxen—Deafness—Docetaxel—head and neck cancer	0.000539	0.00282	CcSEcCtD
Naproxen—Hepatic failure—Docetaxel—head and neck cancer	0.000537	0.00281	CcSEcCtD
Naproxen—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000532	0.00278	CcSEcCtD
Naproxen—Convulsion—Vinblastine—head and neck cancer	0.000531	0.00278	CcSEcCtD
Naproxen—Hypertension—Vinblastine—head and neck cancer	0.000529	0.00277	CcSEcCtD
Naproxen—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000527	0.00276	CcSEcCtD
Naproxen—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000519	0.00271	CcSEcCtD
Naproxen—Pneumonia—Fluorouracil—head and neck cancer	0.000518	0.00271	CcSEcCtD
Naproxen—Anaemia—Hydroxyurea—head and neck cancer	0.000517	0.0027	CcSEcCtD
Naproxen—Discomfort—Vinblastine—head and neck cancer	0.000516	0.0027	CcSEcCtD
Naproxen—Visual disturbance—Docetaxel—head and neck cancer	0.000509	0.00266	CcSEcCtD
Naproxen—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000508	0.00266	CcSEcCtD
Naproxen—Renal impairment—Docetaxel—head and neck cancer	0.000507	0.00265	CcSEcCtD
Naproxen—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000505	0.00264	CcSEcCtD
Naproxen—Myocardial infarction—Fluorouracil—head and neck cancer	0.000505	0.00264	CcSEcCtD
Naproxen—Dermatitis bullous—Docetaxel—head and neck cancer	0.000505	0.00264	CcSEcCtD
Naproxen—Malaise—Hydroxyurea—head and neck cancer	0.000504	0.00264	CcSEcCtD
Naproxen—Stomatitis—Fluorouracil—head and neck cancer	0.000502	0.00263	CcSEcCtD
Naproxen—Indomethacin—PTGS2—head and neck cancer	0.000501	0.0668	CrCbGaD
Naproxen—Urinary tract infection—Fluorouracil—head and neck cancer	0.000501	0.00262	CcSEcCtD
Naproxen—Conjunctivitis—Fluorouracil—head and neck cancer	0.000501	0.00262	CcSEcCtD
Naproxen—Leukopenia—Hydroxyurea—head and neck cancer	0.000501	0.00262	CcSEcCtD
Naproxen—Cardiac failure—Docetaxel—head and neck cancer	0.000494	0.00259	CcSEcCtD
Naproxen—Thrombocytopenia—Vinblastine—head and neck cancer	0.00049	0.00256	CcSEcCtD
Naproxen—Epistaxis—Fluorouracil—head and neck cancer	0.000486	0.00254	CcSEcCtD
Naproxen—Convulsion—Hydroxyurea—head and neck cancer	0.000485	0.00254	CcSEcCtD
Naproxen—Sinusitis—Fluorouracil—head and neck cancer	0.000483	0.00253	CcSEcCtD
Naproxen—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000482	0.00252	CcSEcCtD
Naproxen—Agranulocytosis—Fluorouracil—head and neck cancer	0.000481	0.00252	CcSEcCtD
Naproxen—Anorexia—Vinblastine—head and neck cancer	0.000477	0.0025	CcSEcCtD
Naproxen—Migraine—Docetaxel—head and neck cancer	0.000475	0.00248	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000473	0.00247	CcSEcCtD
Naproxen—Discomfort—Hydroxyurea—head and neck cancer	0.00047	0.00246	CcSEcCtD
Naproxen—Haemoglobin—Fluorouracil—head and neck cancer	0.000465	0.00243	CcSEcCtD
Naproxen—Rhinitis—Fluorouracil—head and neck cancer	0.000464	0.00243	CcSEcCtD
Naproxen—Haemorrhage—Fluorouracil—head and neck cancer	0.000462	0.00242	CcSEcCtD
Naproxen—Pharyngitis—Fluorouracil—head and neck cancer	0.000459	0.0024	CcSEcCtD
Naproxen—Oedema—Hydroxyurea—head and neck cancer	0.000456	0.00239	CcSEcCtD
Naproxen—Infection—Hydroxyurea—head and neck cancer	0.000453	0.00237	CcSEcCtD
Naproxen—Paraesthesia—Vinblastine—head and neck cancer	0.000449	0.00235	CcSEcCtD
Naproxen—Dehydration—Docetaxel—head and neck cancer	0.000449	0.00235	CcSEcCtD
Naproxen—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000448	0.00234	CcSEcCtD
Naproxen—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000447	0.00234	CcSEcCtD
Naproxen—Liver function test abnormal—Docetaxel—head and neck cancer	0.000445	0.00233	CcSEcCtD
Naproxen—Skin disorder—Hydroxyurea—head and neck cancer	0.000443	0.00232	CcSEcCtD
Naproxen—Flurbiprofen—PTGS2—head and neck cancer	0.000443	0.059	CrCbGaD
Naproxen—Dry skin—Docetaxel—head and neck cancer	0.000442	0.00231	CcSEcCtD
Naproxen—Abdominal pain upper—Docetaxel—head and neck cancer	0.000441	0.00231	CcSEcCtD
Naproxen—Breast disorder—Docetaxel—head and neck cancer	0.000436	0.00228	CcSEcCtD
Naproxen—Anorexia—Hydroxyurea—head and neck cancer	0.000435	0.00228	CcSEcCtD
Naproxen—Decreased appetite—Vinblastine—head and neck cancer	0.000435	0.00228	CcSEcCtD
Naproxen—Cramp muscle—Docetaxel—head and neck cancer	0.000434	0.00227	CcSEcCtD
Naproxen—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000434	0.00227	CcSEcCtD
Naproxen—Constipation—Vinblastine—head and neck cancer	0.000428	0.00224	CcSEcCtD
Naproxen—Pain—Vinblastine—head and neck cancer	0.000428	0.00224	CcSEcCtD
Naproxen—Dysphagia—Docetaxel—head and neck cancer	0.000417	0.00218	CcSEcCtD
Naproxen—Arrhythmia—Fluorouracil—head and neck cancer	0.000413	0.00216	CcSEcCtD
Naproxen—Feeling abnormal—Vinblastine—head and neck cancer	0.000412	0.00216	CcSEcCtD
Naproxen—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000409	0.00214	CcSEcCtD
Naproxen—Alopecia—Fluorouracil—head and neck cancer	0.000409	0.00214	CcSEcCtD
Naproxen—Dyspnoea—Hydroxyurea—head and neck cancer	0.000407	0.00213	CcSEcCtD
Naproxen—Angina pectoris—Docetaxel—head and neck cancer	0.000406	0.00213	CcSEcCtD
Naproxen—Somnolence—Hydroxyurea—head and neck cancer	0.000406	0.00212	CcSEcCtD
Naproxen—Erythema—Fluorouracil—head and neck cancer	0.000403	0.00211	CcSEcCtD
Naproxen—Dyspepsia—Hydroxyurea—head and neck cancer	0.000402	0.0021	CcSEcCtD
Naproxen—Ketoprofen—PTGS2—head and neck cancer	0.000401	0.0534	CrCbGaD
Naproxen—Decreased appetite—Hydroxyurea—head and neck cancer	0.000397	0.00208	CcSEcCtD
Naproxen—Pancytopenia—Docetaxel—head and neck cancer	0.000396	0.00207	CcSEcCtD
Naproxen—Abdominal pain—Vinblastine—head and neck cancer	0.000396	0.00207	CcSEcCtD
Naproxen—Ibuprofen—PTGS2—head and neck cancer	0.000394	0.0526	CrCbGaD
Naproxen—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000394	0.00206	CcSEcCtD
Naproxen—Fatigue—Hydroxyurea—head and neck cancer	0.000394	0.00206	CcSEcCtD
Naproxen—Pain—Hydroxyurea—head and neck cancer	0.00039	0.00204	CcSEcCtD
Naproxen—Constipation—Hydroxyurea—head and neck cancer	0.00039	0.00204	CcSEcCtD
Naproxen—Vision blurred—Fluorouracil—head and neck cancer	0.000379	0.00198	CcSEcCtD
Naproxen—Weight decreased—Docetaxel—head and neck cancer	0.000377	0.00197	CcSEcCtD
Naproxen—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000376	0.00197	CcSEcCtD
Naproxen—Pneumonia—Docetaxel—head and neck cancer	0.000374	0.00196	CcSEcCtD
Naproxen—Anaemia—Fluorouracil—head and neck cancer	0.000372	0.00195	CcSEcCtD
Naproxen—Hypersensitivity—Vinblastine—head and neck cancer	0.000369	0.00193	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000369	0.00193	CcSEcCtD
Naproxen—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000367	0.00192	CcSEcCtD
Naproxen—Renal failure—Docetaxel—head and neck cancer	0.000365	0.00191	CcSEcCtD
Naproxen—Myocardial infarction—Docetaxel—head and neck cancer	0.000364	0.00191	CcSEcCtD
Naproxen—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000364	0.00191	CcSEcCtD
Naproxen—Stomatitis—Docetaxel—head and neck cancer	0.000362	0.0019	CcSEcCtD
Naproxen—Jaundice—Docetaxel—head and neck cancer	0.000362	0.0019	CcSEcCtD
Naproxen—Conjunctivitis—Docetaxel—head and neck cancer	0.000361	0.00189	CcSEcCtD
Naproxen—Body temperature increased—Hydroxyurea—head and neck cancer	0.000361	0.00189	CcSEcCtD
Naproxen—Leukopenia—Fluorouracil—head and neck cancer	0.00036	0.00189	CcSEcCtD
Naproxen—Asthenia—Vinblastine—head and neck cancer	0.000359	0.00188	CcSEcCtD
Naproxen—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000352	0.00184	CcSEcCtD
Naproxen—Epistaxis—Docetaxel—head and neck cancer	0.000351	0.00183	CcSEcCtD
Naproxen—Convulsion—Fluorouracil—head and neck cancer	0.000349	0.00182	CcSEcCtD
Naproxen—Agranulocytosis—Docetaxel—head and neck cancer	0.000347	0.00182	CcSEcCtD
Naproxen—Chest pain—Fluorouracil—head and neck cancer	0.000343	0.00179	CcSEcCtD
Naproxen—Myalgia—Fluorouracil—head and neck cancer	0.000343	0.00179	CcSEcCtD
Naproxen—Diarrhoea—Vinblastine—head and neck cancer	0.000342	0.00179	CcSEcCtD
Naproxen—Discomfort—Fluorouracil—head and neck cancer	0.000339	0.00177	CcSEcCtD
Naproxen—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000336	0.00176	CcSEcCtD
Naproxen—Haemoglobin—Docetaxel—head and neck cancer	0.000335	0.00176	CcSEcCtD
Naproxen—Rhinitis—Docetaxel—head and neck cancer	0.000335	0.00175	CcSEcCtD
Naproxen—Haemorrhage—Docetaxel—head and neck cancer	0.000334	0.00175	CcSEcCtD
Naproxen—Hepatitis—Docetaxel—head and neck cancer	0.000334	0.00175	CcSEcCtD
Naproxen—Confusional state—Fluorouracil—head and neck cancer	0.000331	0.00173	CcSEcCtD
Naproxen—Pharyngitis—Docetaxel—head and neck cancer	0.000331	0.00173	CcSEcCtD
Naproxen—Dizziness—Vinblastine—head and neck cancer	0.000331	0.00173	CcSEcCtD
Naproxen—Urinary tract disorder—Docetaxel—head and neck cancer	0.00033	0.00172	CcSEcCtD
Naproxen—Oedema peripheral—Docetaxel—head and neck cancer	0.000329	0.00172	CcSEcCtD
Naproxen—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000329	0.00172	CcSEcCtD
Naproxen—Oedema—Fluorouracil—head and neck cancer	0.000329	0.00172	CcSEcCtD
Naproxen—Connective tissue disorder—Docetaxel—head and neck cancer	0.000328	0.00172	CcSEcCtD
Naproxen—Asthenia—Hydroxyurea—head and neck cancer	0.000327	0.00171	CcSEcCtD
Naproxen—Urethral disorder—Docetaxel—head and neck cancer	0.000327	0.00171	CcSEcCtD
Naproxen—Infection—Fluorouracil—head and neck cancer	0.000326	0.00171	CcSEcCtD
Naproxen—Nervous system disorder—Fluorouracil—head and neck cancer	0.000322	0.00169	CcSEcCtD
Naproxen—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000322	0.00168	CcSEcCtD
Naproxen—Visual impairment—Docetaxel—head and neck cancer	0.000322	0.00168	CcSEcCtD
Naproxen—Tachycardia—Fluorouracil—head and neck cancer	0.000321	0.00168	CcSEcCtD
Naproxen—Vomiting—Vinblastine—head and neck cancer	0.000318	0.00166	CcSEcCtD
Naproxen—Erythema multiforme—Docetaxel—head and neck cancer	0.000316	0.00165	CcSEcCtD
Naproxen—Headache—Vinblastine—head and neck cancer	0.000314	0.00164	CcSEcCtD
Naproxen—Anorexia—Fluorouracil—head and neck cancer	0.000313	0.00164	CcSEcCtD
Naproxen—Diarrhoea—Hydroxyurea—head and neck cancer	0.000312	0.00163	CcSEcCtD
Naproxen—Eye disorder—Docetaxel—head and neck cancer	0.000312	0.00163	CcSEcCtD
Naproxen—Cardiac disorder—Docetaxel—head and neck cancer	0.00031	0.00162	CcSEcCtD
Naproxen—Hypotension—Fluorouracil—head and neck cancer	0.000307	0.00161	CcSEcCtD
Naproxen—Angiopathy—Docetaxel—head and neck cancer	0.000303	0.00158	CcSEcCtD
Naproxen—Dizziness—Hydroxyurea—head and neck cancer	0.000302	0.00158	CcSEcCtD
Naproxen—Immune system disorder—Docetaxel—head and neck cancer	0.000301	0.00158	CcSEcCtD
Naproxen—Mediastinal disorder—Docetaxel—head and neck cancer	0.000301	0.00157	CcSEcCtD
Naproxen—Chills—Docetaxel—head and neck cancer	0.000299	0.00157	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000299	0.00157	CcSEcCtD
Naproxen—Arrhythmia—Docetaxel—head and neck cancer	0.000298	0.00156	CcSEcCtD
Naproxen—Nausea—Vinblastine—head and neck cancer	0.000297	0.00156	CcSEcCtD
Naproxen—Insomnia—Fluorouracil—head and neck cancer	0.000297	0.00155	CcSEcCtD
Naproxen—Paraesthesia—Fluorouracil—head and neck cancer	0.000295	0.00154	CcSEcCtD
Naproxen—Alopecia—Docetaxel—head and neck cancer	0.000295	0.00154	CcSEcCtD
Naproxen—Dyspnoea—Fluorouracil—head and neck cancer	0.000293	0.00153	CcSEcCtD
Naproxen—Mental disorder—Docetaxel—head and neck cancer	0.000292	0.00153	CcSEcCtD
Naproxen—Somnolence—Fluorouracil—head and neck cancer	0.000292	0.00153	CcSEcCtD
Naproxen—Malnutrition—Docetaxel—head and neck cancer	0.000291	0.00152	CcSEcCtD
Naproxen—Erythema—Docetaxel—head and neck cancer	0.000291	0.00152	CcSEcCtD
Naproxen—Vomiting—Hydroxyurea—head and neck cancer	0.00029	0.00152	CcSEcCtD
Naproxen—Dyspepsia—Fluorouracil—head and neck cancer	0.000289	0.00151	CcSEcCtD
Naproxen—Rash—Hydroxyurea—head and neck cancer	0.000288	0.00151	CcSEcCtD
Naproxen—Dermatitis—Hydroxyurea—head and neck cancer	0.000288	0.0015	CcSEcCtD
Naproxen—Headache—Hydroxyurea—head and neck cancer	0.000286	0.0015	CcSEcCtD
Naproxen—Decreased appetite—Fluorouracil—head and neck cancer	0.000286	0.00149	CcSEcCtD
Naproxen—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000284	0.00148	CcSEcCtD
Naproxen—Pain—Fluorouracil—head and neck cancer	0.000281	0.00147	CcSEcCtD
Naproxen—Muscle spasms—Docetaxel—head and neck cancer	0.000279	0.00146	CcSEcCtD
Naproxen—Nausea—Hydroxyurea—head and neck cancer	0.000271	0.00142	CcSEcCtD
Naproxen—Feeling abnormal—Fluorouracil—head and neck cancer	0.000271	0.00142	CcSEcCtD
Naproxen—Anaemia—Docetaxel—head and neck cancer	0.000269	0.00141	CcSEcCtD
Naproxen—Urticaria—Fluorouracil—head and neck cancer	0.000261	0.00137	CcSEcCtD
Naproxen—Syncope—Docetaxel—head and neck cancer	0.000261	0.00136	CcSEcCtD
Naproxen—Leukopenia—Docetaxel—head and neck cancer	0.00026	0.00136	CcSEcCtD
Naproxen—Body temperature increased—Fluorouracil—head and neck cancer	0.00026	0.00136	CcSEcCtD
Naproxen—Palpitations—Docetaxel—head and neck cancer	0.000257	0.00134	CcSEcCtD
Naproxen—Loss of consciousness—Docetaxel—head and neck cancer	0.000255	0.00134	CcSEcCtD
Naproxen—Cough—Docetaxel—head and neck cancer	0.000254	0.00133	CcSEcCtD
Naproxen—Convulsion—Docetaxel—head and neck cancer	0.000252	0.00132	CcSEcCtD
Naproxen—Hypertension—Docetaxel—head and neck cancer	0.000251	0.00131	CcSEcCtD
Naproxen—Arthralgia—Docetaxel—head and neck cancer	0.000247	0.00129	CcSEcCtD
Naproxen—Chest pain—Docetaxel—head and neck cancer	0.000247	0.00129	CcSEcCtD
Naproxen—Myalgia—Docetaxel—head and neck cancer	0.000247	0.00129	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000246	0.00129	CcSEcCtD
Naproxen—Hypersensitivity—Fluorouracil—head and neck cancer	0.000242	0.00127	CcSEcCtD
Naproxen—Dry mouth—Docetaxel—head and neck cancer	0.000242	0.00127	CcSEcCtD
Naproxen—Confusional state—Docetaxel—head and neck cancer	0.000239	0.00125	CcSEcCtD
Naproxen—Anaphylactic shock—Docetaxel—head and neck cancer	0.000237	0.00124	CcSEcCtD
Naproxen—Oedema—Docetaxel—head and neck cancer	0.000237	0.00124	CcSEcCtD
Naproxen—Infection—Docetaxel—head and neck cancer	0.000236	0.00123	CcSEcCtD
Naproxen—Shock—Docetaxel—head and neck cancer	0.000233	0.00122	CcSEcCtD
Naproxen—Nervous system disorder—Docetaxel—head and neck cancer	0.000233	0.00122	CcSEcCtD
Naproxen—Pruritus—Fluorouracil—head and neck cancer	0.000232	0.00122	CcSEcCtD
Naproxen—Thrombocytopenia—Docetaxel—head and neck cancer	0.000232	0.00121	CcSEcCtD
Naproxen—Tachycardia—Docetaxel—head and neck cancer	0.000231	0.00121	CcSEcCtD
Naproxen—Skin disorder—Docetaxel—head and neck cancer	0.00023	0.00121	CcSEcCtD
Naproxen—Anorexia—Docetaxel—head and neck cancer	0.000226	0.00118	CcSEcCtD
Naproxen—Diarrhoea—Fluorouracil—head and neck cancer	0.000225	0.00118	CcSEcCtD
Naproxen—Hypotension—Docetaxel—head and neck cancer	0.000222	0.00116	CcSEcCtD
Naproxen—Dizziness—Fluorouracil—head and neck cancer	0.000217	0.00114	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000216	0.00113	CcSEcCtD
Naproxen—Insomnia—Docetaxel—head and neck cancer	0.000214	0.00112	CcSEcCtD
Naproxen—Paraesthesia—Docetaxel—head and neck cancer	0.000213	0.00111	CcSEcCtD
Naproxen—Dyspnoea—Docetaxel—head and neck cancer	0.000211	0.00111	CcSEcCtD
Naproxen—Somnolence—Docetaxel—head and neck cancer	0.000211	0.0011	CcSEcCtD
Naproxen—Vomiting—Fluorouracil—head and neck cancer	0.000209	0.00109	CcSEcCtD
Naproxen—Dyspepsia—Docetaxel—head and neck cancer	0.000209	0.00109	CcSEcCtD
Naproxen—Rash—Fluorouracil—head and neck cancer	0.000207	0.00108	CcSEcCtD
Naproxen—Dermatitis—Fluorouracil—head and neck cancer	0.000207	0.00108	CcSEcCtD
Naproxen—Decreased appetite—Docetaxel—head and neck cancer	0.000206	0.00108	CcSEcCtD
Naproxen—Headache—Fluorouracil—head and neck cancer	0.000206	0.00108	CcSEcCtD
Naproxen—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000205	0.00107	CcSEcCtD
Naproxen—Fatigue—Docetaxel—head and neck cancer	0.000204	0.00107	CcSEcCtD
Naproxen—Pain—Docetaxel—head and neck cancer	0.000203	0.00106	CcSEcCtD
Naproxen—Constipation—Docetaxel—head and neck cancer	0.000203	0.00106	CcSEcCtD
Naproxen—Feeling abnormal—Docetaxel—head and neck cancer	0.000195	0.00102	CcSEcCtD
Naproxen—Nausea—Fluorouracil—head and neck cancer	0.000195	0.00102	CcSEcCtD
Naproxen—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000194	0.00101	CcSEcCtD
Naproxen—Abdominal pain—Docetaxel—head and neck cancer	0.000187	0.000981	CcSEcCtD
Naproxen—Body temperature increased—Docetaxel—head and neck cancer	0.000187	0.000981	CcSEcCtD
Naproxen—Hypersensitivity—Docetaxel—head and neck cancer	0.000175	0.000914	CcSEcCtD
Naproxen—Asthenia—Docetaxel—head and neck cancer	0.00017	0.00089	CcSEcCtD
Naproxen—Pruritus—Docetaxel—head and neck cancer	0.000168	0.000878	CcSEcCtD
Naproxen—Diarrhoea—Docetaxel—head and neck cancer	0.000162	0.000849	CcSEcCtD
Naproxen—Dizziness—Docetaxel—head and neck cancer	0.000157	0.00082	CcSEcCtD
Naproxen—Vomiting—Docetaxel—head and neck cancer	0.000151	0.000789	CcSEcCtD
Naproxen—Rash—Docetaxel—head and neck cancer	0.00015	0.000782	CcSEcCtD
Naproxen—Dermatitis—Docetaxel—head and neck cancer	0.000149	0.000782	CcSEcCtD
Naproxen—Headache—Docetaxel—head and neck cancer	0.000149	0.000777	CcSEcCtD
Naproxen—Nausea—Docetaxel—head and neck cancer	0.000141	0.000737	CcSEcCtD
Naproxen—ALB—Folate Metabolism—IL2—head and neck cancer	0.000115	0.0015	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—CCND1—head and neck cancer	0.000115	0.00149	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—DPYD—head and neck cancer	0.000111	0.00145	CbGpPWpGaD
Naproxen—CYP1A2—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000109	0.00141	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	0.000108	0.0014	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—UROD—head and neck cancer	0.000106	0.00138	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—YAP1—head and neck cancer	0.000106	0.00138	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000103	0.00134	CbGpPWpGaD
Naproxen—CYP2C8—Biological oxidations—GSTM1—head and neck cancer	0.000103	0.00134	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—GRP—head and neck cancer	0.000103	0.00134	CbGpPWpGaD
Naproxen—CYP2C8—Metapathway biotransformation—GSTM1—head and neck cancer	0.000102	0.00132	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—STAT6—head and neck cancer	0.0001	0.0013	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—PTGS2—head and neck cancer	9.89e-05	0.00129	CbGpPWpGaD
Naproxen—CYP2C8—Biological oxidations—CYP1A1—head and neck cancer	9.79e-05	0.00127	CbGpPWpGaD
Naproxen—CYP2C8—Metapathway biotransformation—CYP1A1—head and neck cancer	9.65e-05	0.00126	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—ATP7B—head and neck cancer	9.6e-05	0.00125	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	9.16e-05	0.00119	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL2—head and neck cancer	8.96e-05	0.00117	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—YAP1—head and neck cancer	8.85e-05	0.00115	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—CCND1—head and neck cancer	8.74e-05	0.00114	CbGpPWpGaD
Naproxen—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—head and neck cancer	8.66e-05	0.00113	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—UROD—head and neck cancer	8.61e-05	0.00112	CbGpPWpGaD
Naproxen—ALB—Metabolism—UROD—head and neck cancer	8.56e-05	0.00111	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—VEGFA—head and neck cancer	8.41e-05	0.00109	CbGpPWpGaD
Naproxen—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	8.4e-05	0.00109	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—NAT2—head and neck cancer	8.36e-05	0.00109	CbGpPWpGaD
Naproxen—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	8.29e-05	0.00108	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	8.24e-05	0.00107	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	8.24e-05	0.00107	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	8.24e-05	0.00107	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	8.21e-05	0.00107	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	8.07e-05	0.00105	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—head and neck cancer	8.01e-05	0.00104	CbGpPWpGaD
Naproxen—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	7.97e-05	0.00104	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	7.95e-05	0.00103	CbGpPWpGaD
Naproxen—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	7.86e-05	0.00102	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	7.73e-05	0.001	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	7.65e-05	0.000995	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—TP53—head and neck cancer	7.41e-05	0.000964	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—DPYD—head and neck cancer	7.33e-05	0.000953	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—NAT2—head and neck cancer	7.28e-05	0.000946	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—HRAS—head and neck cancer	7.22e-05	0.000939	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—MAPK3—head and neck cancer	7.21e-05	0.000937	CbGpPWpGaD
Naproxen—CYP1A2—Biological oxidations—GSTM1—head and neck cancer	7.18e-05	0.000934	CbGpPWpGaD
Naproxen—CYP1A2—Metapathway biotransformation—GSTM1—head and neck cancer	7.08e-05	0.000921	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—UROD—head and neck cancer	7.01e-05	0.000911	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—YAP1—head and neck cancer	6.95e-05	0.000904	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	6.93e-05	0.000902	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	6.92e-05	0.000901	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—MAPK1—head and neck cancer	6.86e-05	0.000892	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—EGFR—head and neck cancer	6.86e-05	0.000891	CbGpPWpGaD
Naproxen—CYP1A2—Biological oxidations—CYP1A1—head and neck cancer	6.81e-05	0.000885	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—NAT2—head and neck cancer	6.79e-05	0.000883	CbGpPWpGaD
Naproxen—CYP1A2—Metapathway biotransformation—CYP1A1—head and neck cancer	6.71e-05	0.000873	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	6.68e-05	0.000869	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	6.64e-05	0.000864	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	6.62e-05	0.000861	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—DPYD—head and neck cancer	6.38e-05	0.00083	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—TYMS—head and neck cancer	6.35e-05	0.000826	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—GSTM1—head and neck cancer	6.28e-05	0.000817	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—YAP1—head and neck cancer	6.05e-05	0.000787	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—GPX1—head and neck cancer	6.01e-05	0.000782	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—UROD—head and neck cancer	5.99e-05	0.000779	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—DPYD—head and neck cancer	5.95e-05	0.000774	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—CYP1A1—head and neck cancer	5.95e-05	0.000774	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	5.94e-05	0.000773	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	5.88e-05	0.000764	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	5.82e-05	0.000757	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TP53—head and neck cancer	5.76e-05	0.000748	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	5.74e-05	0.000746	CbGpPWpGaD
Naproxen—AKR1C3—Disease—NOTCH1—head and neck cancer	5.69e-05	0.00074	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—YAP1—head and neck cancer	5.65e-05	0.000735	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—NAT2—head and neck cancer	5.53e-05	0.00072	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	5.44e-05	0.000707	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	5.18e-05	0.000674	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	4.9e-05	0.000637	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.89e-05	0.000636	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—DPYD—head and neck cancer	4.85e-05	0.000631	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	4.67e-05	0.000607	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	4.66e-05	0.000607	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	4.66e-05	0.000606	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	4.65e-05	0.000604	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	4.62e-05	0.000601	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—YAP1—head and neck cancer	4.61e-05	0.000599	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	4.55e-05	0.000592	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—NAT2—head and neck cancer	4.39e-05	0.000571	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—IL2—head and neck cancer	4.39e-05	0.000571	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTGS2—head and neck cancer	4.23e-05	0.00055	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—TYMS—head and neck cancer	4.17e-05	0.000543	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GSTM1—head and neck cancer	4.13e-05	0.000537	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	4.05e-05	0.000526	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NOTCH1—head and neck cancer	3.99e-05	0.000519	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	3.97e-05	0.000516	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GPX1—head and neck cancer	3.95e-05	0.000514	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	3.92e-05	0.000509	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CYP1A1—head and neck cancer	3.91e-05	0.000509	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—DPYD—head and neck cancer	3.85e-05	0.000501	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.8e-05	0.000494	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.78e-05	0.000491	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.76e-05	0.000489	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.74e-05	0.000486	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—VEGFA—head and neck cancer	3.73e-05	0.000485	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTEN—head and neck cancer	3.69e-05	0.000479	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—YAP1—head and neck cancer	3.66e-05	0.000475	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—TYMS—head and neck cancer	3.64e-05	0.000473	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GSTM1—head and neck cancer	3.59e-05	0.000467	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NAT2—head and neck cancer	3.58e-05	0.000465	CbGpPWpGaD
Naproxen—ALB—Metabolism—NAT2—head and neck cancer	3.55e-05	0.000462	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTGS2—head and neck cancer	3.54e-05	0.00046	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	3.53e-05	0.000459	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	3.46e-05	0.00045	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GPX1—head and neck cancer	3.44e-05	0.000447	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CYP1A1—head and neck cancer	3.41e-05	0.000443	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—TYMS—head and neck cancer	3.39e-05	0.000441	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	3.36e-05	0.000437	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GSTM1—head and neck cancer	3.35e-05	0.000436	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	3.31e-05	0.00043	CbGpPWpGaD
Naproxen—AKR1C3—Disease—STAT3—head and neck cancer	3.3e-05	0.000429	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GPX1—head and neck cancer	3.21e-05	0.000418	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CYP1A1—head and neck cancer	3.18e-05	0.000413	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MAPK3—head and neck cancer	3.15e-05	0.00041	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—DPYD—head and neck cancer	3.13e-05	0.000408	CbGpPWpGaD
Naproxen—ALB—Metabolism—DPYD—head and neck cancer	3.12e-05	0.000405	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.09e-05	0.000402	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTEN—head and neck cancer	3.09e-05	0.000402	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.06e-05	0.000398	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	3.02e-05	0.000392	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MAPK1—head and neck cancer	3e-05	0.00039	CbGpPWpGaD
Naproxen—AKR1C3—Disease—EGFR—head and neck cancer	3e-05	0.00039	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—YAP1—head and neck cancer	2.97e-05	0.000387	CbGpPWpGaD
Naproxen—ALB—Metabolism—YAP1—head and neck cancer	2.96e-05	0.000385	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	2.91e-05	0.000379	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NAT2—head and neck cancer	2.91e-05	0.000378	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.8e-05	0.000364	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—TYMS—head and neck cancer	2.77e-05	0.00036	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL2—head and neck cancer	2.74e-05	0.000357	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GSTM1—head and neck cancer	2.73e-05	0.000355	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCND1—head and neck cancer	2.67e-05	0.000348	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.64e-05	0.000343	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GPX1—head and neck cancer	2.62e-05	0.00034	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.61e-05	0.00034	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PIK3CA—head and neck cancer	2.6e-05	0.000338	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP1A1—head and neck cancer	2.59e-05	0.000337	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTEN—head and neck cancer	2.58e-05	0.000336	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—DPYD—head and neck cancer	2.55e-05	0.000332	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NAT2—head and neck cancer	2.49e-05	0.000323	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—YAP1—head and neck cancer	2.42e-05	0.000315	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HRAS—head and neck cancer	2.41e-05	0.000313	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.4e-05	0.000312	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	2.38e-05	0.00031	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—head and neck cancer	2.33e-05	0.000303	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—head and neck cancer	2.33e-05	0.000303	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—STAT3—head and neck cancer	2.31e-05	0.0003	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IL2—head and neck cancer	2.26e-05	0.000294	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.24e-05	0.000291	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.22e-05	0.000289	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MAPK3—head and neck cancer	2.21e-05	0.000287	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—TYMS—head and neck cancer	2.2e-05	0.000285	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—DPYD—head and neck cancer	2.18e-05	0.000284	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PIK3CA—head and neck cancer	2.18e-05	0.000283	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTM1—head and neck cancer	2.17e-05	0.000282	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.13e-05	0.000277	CbGpPWpGaD
Naproxen—AKR1C3—Disease—AKT1—head and neck cancer	2.12e-05	0.000276	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MAPK1—head and neck cancer	2.1e-05	0.000273	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EGFR—head and neck cancer	2.1e-05	0.000273	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GPX1—head and neck cancer	2.08e-05	0.00027	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—YAP1—head and neck cancer	2.07e-05	0.000269	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP1A1—head and neck cancer	2.06e-05	0.000268	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTEN—head and neck cancer	2.03e-05	0.000264	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—head and neck cancer	2.03e-05	0.000263	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOTCH1—head and neck cancer	1.97e-05	0.000256	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.95e-05	0.000253	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.94e-05	0.000252	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—head and neck cancer	1.92e-05	0.00025	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—head and neck cancer	1.89e-05	0.000246	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CA—head and neck cancer	1.82e-05	0.000237	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.82e-05	0.000237	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MAPK3—head and neck cancer	1.82e-05	0.000237	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—TYMS—head and neck cancer	1.79e-05	0.000232	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AKT1—head and neck cancer	1.78e-05	0.000231	CbGpPWpGaD
Naproxen—ALB—Metabolism—TYMS—head and neck cancer	1.78e-05	0.000231	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTEN—head and neck cancer	1.77e-05	0.00023	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTM1—head and neck cancer	1.77e-05	0.00023	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—head and neck cancer	1.76e-05	0.000229	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTM1—head and neck cancer	1.76e-05	0.000228	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MAPK1—head and neck cancer	1.73e-05	0.000225	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GPX1—head and neck cancer	1.69e-05	0.00022	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.69e-05	0.00022	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HRAS—head and neck cancer	1.69e-05	0.000219	CbGpPWpGaD
Naproxen—ALB—Metabolism—GPX1—head and neck cancer	1.68e-05	0.000219	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP1A1—head and neck cancer	1.67e-05	0.000218	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP1A1—head and neck cancer	1.66e-05	0.000216	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTEN—head and neck cancer	1.65e-05	0.000214	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.59e-05	0.000206	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.55e-05	0.000202	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—head and neck cancer	1.54e-05	0.0002	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CA—head and neck cancer	1.5e-05	0.000195	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AKT1—head and neck cancer	1.49e-05	0.000193	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—TYMS—head and neck cancer	1.45e-05	0.000189	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—head and neck cancer	1.45e-05	0.000189	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTM1—head and neck cancer	1.44e-05	0.000187	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CA—head and neck cancer	1.43e-05	0.000186	CbGpPWpGaD
Naproxen—ALB—Hemostasis—HRAS—head and neck cancer	1.39e-05	0.000181	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GPX1—head and neck cancer	1.38e-05	0.000179	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.38e-05	0.000179	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.37e-05	0.000178	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP1A1—head and neck cancer	1.36e-05	0.000177	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.36e-05	0.000176	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTEN—head and neck cancer	1.34e-05	0.000175	CbGpPWpGaD
Naproxen—PTGS2—Disease—PTEN—head and neck cancer	1.27e-05	0.000166	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CA—head and neck cancer	1.25e-05	0.000162	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—TYMS—head and neck cancer	1.24e-05	0.000162	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTM1—head and neck cancer	1.23e-05	0.00016	CbGpPWpGaD
Naproxen—ALB—Hemostasis—AKT1—head and neck cancer	1.23e-05	0.00016	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GPX1—head and neck cancer	1.18e-05	0.000153	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AKT1—head and neck cancer	1.17e-05	0.000152	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP1A1—head and neck cancer	1.16e-05	0.000151	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CA—head and neck cancer	1.16e-05	0.000151	CbGpPWpGaD
Naproxen—PTGS2—Disease—STAT3—head and neck cancer	1.14e-05	0.000148	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.12e-05	0.000146	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAPK3—head and neck cancer	1.09e-05	0.000142	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTEN—head and neck cancer	1.07e-05	0.000139	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAPK1—head and neck cancer	1.04e-05	0.000135	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGFR—head and neck cancer	1.04e-05	0.000135	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AKT1—head and neck cancer	1.02e-05	0.000132	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—head and neck cancer	9.95e-06	0.000129	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—head and neck cancer	9.9e-06	0.000129	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	9.56e-06	0.000124	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AKT1—head and neck cancer	9.5e-06	0.000124	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CA—head and neck cancer	9.48e-06	0.000123	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CA—head and neck cancer	8.99e-06	0.000117	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTEN—head and neck cancer	8.68e-06	0.000113	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTEN—head and neck cancer	8.63e-06	0.000112	CbGpPWpGaD
Naproxen—PTGS2—Disease—HRAS—head and neck cancer	8.31e-06	0.000108	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—head and neck cancer	8.1e-06	0.000105	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AKT1—head and neck cancer	7.75e-06	0.000101	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CA—head and neck cancer	7.53e-06	9.79e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKT1—head and neck cancer	7.34e-06	9.55e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTEN—head and neck cancer	7.07e-06	9.19e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—head and neck cancer	6.92e-06	9e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKT1—head and neck cancer	6.15e-06	8e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CA—head and neck cancer	6.12e-06	7.96e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CA—head and neck cancer	6.09e-06	7.92e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTEN—head and neck cancer	6.04e-06	7.85e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKT1—head and neck cancer	5e-06	6.51e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CA—head and neck cancer	4.98e-06	6.48e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKT1—head and neck cancer	4.97e-06	6.47e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CA—head and neck cancer	4.26e-06	5.54e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKT1—head and neck cancer	4.07e-06	5.29e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKT1—head and neck cancer	3.48e-06	4.52e-05	CbGpPWpGaD
